Table 2.

Cancer risk in 15,636 patients with primary Sjögren syndrome (list includes only cancer number ≥ 5).

Specific Cancer	Observed	Expected	SIR (95% CI)	p
All	741	521.52	1.4 (1.3–1.5)	< 0.001^*
Nonhematological	657	500.03	1.3 (1.2–1.4)	< 0.001^*
Mouth	24	10.46	2.3 (1.5–3.4)	< 0.001^*
Nasopharynx	11	5.95	1.8 (0.9–3.3)	0.08
Esophagus	8	4.59	1.7 (0.8–3.4)	0.19
Stomach	23	24.91	0.9 (0.6–1.4)	0.80
Colorectal	48	77.48	0.6 (0.5–0.8)	< 0.001^*
Liver	94	55.86	1.7 (1.4–2.1)	< 0.001^*
Gall bladder	7	7.44	0.9 (0.4–1.9)	0.93
Pancreas	10	9.89	1.0 (0.5–1.9)	1.00
Lung	90	58.19	1.5 (1.2–1.9)	< 0.001^*
Skin	18	10.77	1.7 (1.0–2.6)	0.05
Breast	124	92.47	1.3 (1.1–1.6)	0.002^*
Uterus	32	42.55	0.8 (0.5–1.1)	0.11
Ovary	20	11.15	1.8 (1.1–2.8)	0.02^*
Prostate	20	11.60	1.7 (1.1–2.7)	0.03^*
Bladder	20	14.29	1.4 (0.9–2.2)	0.18
Kidney	19	14.70	1.3 (0.8–2.0)	0.32
Brain	7	4.73	1.5 (0.6–3.0)	0.40
Thyroid gland	42	14.41	2.9 (2.1–3.9)	< 0.001^*
Hematological	84	21.49	3.9 (3.1–4.8)	< 0.001^*
NHL	51	11.11	4.6 (3.4–6.0)	< 0.001^*
Multiple myeloma	13	3.09	4.2 (2.2–7.2)	< 0.001^*
Leukemia	20	6.92	2.9 (1.8–4.5)	< 0.001^*